hmgcoa reductase

Cerivastatin is an orally active and highly effective HMG-CoA reductase inhibitor with anticancer and lipid-lowering effects. Cerivastatin can reduce low-density lipoprotein cholesterol levels, inhibit the proliferation and invasion of MDA-MB-231 cells, and can be used to study primary hyperlipidemia.

Atorvastatin Sodium (Lipitor) is a competitive inhibitor of HMG-CoA reductase and increases the expression of low density lipoprotein (LDL) receptors on hepatocytes. Atorvastatin Sodium treatment inhibits aquaporin 4 to reduce ischaemic brain oedema.

Tenivastatin (Simvastatin acid) is an anti-hyperlipidemic HMG-CoA reductase inhibitor that inhibits the production of reactive oxygen species (ROS) and can be used in the study of primary hyperlipidemia.

Crilvastatin (PMD 387) is a novel, non-competitive hydroxymethylglutaryl coenzyme A reductase inhibitor with cholesterol-lowering activity, inhibiting cholesterol uptake in rats with hereditary hypercholesterolemia.

Dalvastatin (RG-12561) is an orally available inhibitor of HMG-CoA reductase and cholesterol-lowering synthesis.Dalvastatin competitively inhibits rat hepatic HMG-CoA reductase with an IC50 value of 3.4 nmol / l. Dalvastatin inhibits cholesterol biosynthesis in liver sections in rat experiments with an ED50 value of 0.9.

Apomine (SR-9223i), an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and has been implicated in the regulation of myeloma in vivo. Apomine accelerates the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase and stimulates low-density lipoprotein receptor activity. Apomine enhances the antitumor effect of lovastatin on myeloma cells by downregulating 3-hydroxy-3-methylglutaryl-CoA reductase.

(3R,5R)-Rosuvastatin, the (3R,5R)-enantiomer of Rosuvastatin, is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM.

(3S,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin, a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM.

Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum. Mevastatin was the first statin to enter clinical trials.

Simvastatin (MK 733) is an HMG-CoA reductase inhibitor (Ki=0.2 nM) with oral activity. Simvastatin has hypolipidemic activity, inhibits hepatic production of cholesterol, and is also used for the prevention of cardiovascular disease.

Lovastatin (MK-803) is an HMG-CoA reductase inhibitor (IC50=3.4 nM). Lovastatin lowers cholesterol and is commonly used as a lipid-lowering agent in the treatment of hypercholesterolemia.

Fluvastatin sodium (Fluvastatin sodium salt), a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), is a commonly used cholesterol lowering agent.

Rosuvastatin calcium (ZD4522) , a selective and competitive inhibitor of hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, has antilipidemic activity.

Pitavastatin calcium (NK-104) is a potent inhibitor of HMG-CoA reductase (Ki: 1.7 nM). It lowers both total cholesterol and low-density lipoprotein cholesterol in animals and humans. Metabolism of pitavastatin by the cytochrome P450 system is minimal, reducing the risk of drug-drug interactions.

Atorvastatin hemicalcium salt (Atorvastatin Calcium) is an HMG-CoA reductase inhibitor with oral activity. Atorvastatin hemicalcium salt is used to lower cholesterol.

alpha-Asarone (trans-Asarone) is a psychoactive compound with antidepressant-like activity in mice.

Dim16 HCl is a dual inhibitor of PCSK9 and HMG-CoA reductase that exhibits an IC50 value of 19 nM for PCSK9, potently blocks PCSK9–LDLR binding with an IC50 of 0.8 nM, and increases LDL uptake in HepG2 cells, supporting its use in lipid metabolism and cardiovascular research.

Pravastatin sodium (CS-514 (sodium)), an HMG-CoA reductase inhibitor, inhibits sterol synthesis with IC50 of 5.6 μM.

2'-Ethyl Simvastatin is a Mevinolin analog with HMG-CoA reductase inhibition.

Anhydrosimvastatin (Dehydro simvastatin) is an impurity of Simvastatin. Simvastatin is an HMG-CoA reductase inhibitor.

Cerivastatin sodium (BAY W 6228 sodium) is an orally active and highly potent HMG-CoA reductase inhibitor with lipid-lowering activity that can reduce low-density lipoprotein cholesterol levels. Cerivastatin sodium has anticancer effects and can be used to study primary hyperlipidemia.

HMG499 is a potent and selective HMG-CoA reductase inhibitor with an IC50 of 0.41 μM, capable of eliminating statins-induced accumulation of HMGCR, lowering serum cholesterol levels, and decreasing atherosclerosis [1].

Monacolin J (Antibiotic MB 530A) is a cholesterol biosynthesis inhibitor.

Pitavastatin lactone is the major metabolite of Pitavastatin in humans.Pitavastatin is a competitive inhibitor of HMG-CoA reductase.